

Cell Reports, Volume 26

Supplemental Information

**Single-Cell Resolution and Quantitation
of Targeted Glucocorticoid Delivery in the Thymus**

Matthew D. Taves, Paul R. Mittelstadt, Diego M. Presman, Gordon L. Hager, and Jonathan D. Ashwell




Figure S1. Simultaneous permeabilization and fixation (*perm-fix*) retains liganded glucocorticoid receptor. Related to Figure 1 and 3.

(A) 3617 cells expressing a GFP-glucocorticoid receptor (GFP-GR) fusion protein were cultured in steroid-free medium, incubated for 60 min with or without 10^{-6} M corticosterone (Cort), and trypsinized. Cells were then kept on ice (Live), briefly washed in permeabilization buffer (eBioscience) and fixed with the eBioscience transcription factor fixation reagent (Wash → *perm-fix*), or fixed and washed in permeabilization buffer (*Perm-fix* → wash). GFP-GR median fluorescence index (MFI) values in insets. Data were acquired by flow cytometry.

(B) Relative change in GFP-GR MFI values after corticosterone treatment, for (a).

(C) Relative change in 3617 cell GFP-GR MFI values after corticosterone treatment, simultaneous *perm-fix* with the indicated permeabilization buffer and methanol-free or methanol-containing formaldehyde, and acquisition by flow cytometry.

(D) GFP-GR expressing 3617 cells were incubated in the absence or presence of corticosterone for 15 min, then kept on ice (“Live”), fixed with BD Cytofix/Cytoperm, or fixed with eBioscience FoxP3 transcription factor fixative reagent. Cell were washed and GFP-GR quantified by flow cytometry.

(E) 3617 cells expressing a GFP-androgen receptor (GFP-AR), mCherry-estrogen receptor (mCh-ER), GFP-GR, or GFP-progesterone receptor β (GFP-PR) fusion proteins were cultured in steroid-free medium, incubated for 20 min with or without 10^{-6} M steroid (testosterone, 17β -estradiol, corticosterone, or progesterone, respectively), then kept on ice (“Live”), fixed, or *perm-fixed*. Cell were quantified by flow cytometry. Data are presented as the relative increase in fluorescence of steroid-treated versus untreated samples.




Figure S2. Antibody GR staining and permeabilization-fixation conditions in mouse thymocytes. Related to Figure 4.

(A) 3617 cells expressing the wild-type GR (GFP-GR^{wt}), dimerization-impaired GR (GFP-GR^{mon}), or deficient for GR (KO) were treated with different concentrations of corticosterone, perm-fixed, stained with anti-GR antibody (clone G-5) and a secondary Alexa 647-conjugated anti-mouse antibody, and data acquired by flow cytometry. Live cell GFP-GR MFI values are shown in Fig. 2c).

(B) WT and GR^{lck-Cre} mouse thymocytes were surface stained, fixed, and stained for GR using the specified monoclonal antibodies. The 5E4 antibody was directly conjugated to FITC, while BuGR2 and G-5 were detected with a secondary Alexa 594-conjugated anti-mouse antibody. CD4⁺8⁺ DP thymocytes are shown.

(C) WT mouse thymocytes were incubated with or without 10⁻⁶ M corticosterone, perm-fixed with the indicated combination of permeabilization buffer and formaldehyde, and stained for GR using an Alexa 488-conjugated G-5 monoclonal antibody. The relative increase in MFI after corticosterone treatment is shown.

(D) WT mouse thymocytes were incubated in medium containing the specified amount of corticosterone, surface markers were stained, cells perm-fixed, and GR stained with D8H2-Alexa 488 or 5E4-FITC monoclonal antibodies (G-5-Alexa 488 shown in Fig. 4b).

(E) WT mouse thymocytes were incubated for 20 min in medium containing 10⁻⁷ M corticosterone, washed twice and incubated in steroid-free medium, and collected at the indicated times. One aliquot was fixed in 1% formaldehyde and ChIP-qPCR performed to quantitate GR binding to the *Tsc22d3* (Gilz) gene promoter. Another aliquot was perm-fixed, GR stained, and counted by flow cytometry.




Figure S3. Dose-response of perm-fixed GFP-GR mouse thymocytes and flow cytometry gating strategies. Related to Figures 6 and 7.

(A) Primary thymocytes from GFP-GR knockin mice were incubated in the indicated corticosterone concentrations for 20 min, fixed or perm-fixed, and cells measured by flow cytometry.

(B) Flow cytometry gating strategy for blood and spleen lymphocytes (adult mouse blood sample shown).

(C) Flow cytometry gating strategy for thymocyte subsets (neonatal mouse thymus shown).